By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Kyowa Hakko 

767 3rd Ave., 19th Floor

New York  New York  10017  U.S.A.
Phone: 212-319-5353 Fax: 212-421-1283




Pharmagene Laboratories Limited  Phase ZERO(TM) products and services.

Company News
Kyowa Hakko Release: Groundbreaking Study In Journal Of Attention Disorders Finds That Daily Cognizin Citicoline Oral Supplement Improves Attention In Adolescent Males 8/11/2015 7:24:32 AM
Kyowa Hakko Release: New Survey Shows Americans Fear Mental Deterioration Over Physical Decline 3/18/2015 7:25:16 AM
Kyowa Hakko Release: Cognitive-Enhancing Citicoline Found To Improve Motor Speed And Attention In Adolescents 7/29/2014 9:07:28 AM
Drugmakers Like Merck & Co., Inc. (MRK), Kyowa Hakko Turn To Coffee For New Parkinson’s And Alzheimer’s Treatments 3/17/2014 8:04:37 AM
Dicerna Pharmaceuticals Snags Deal With Japan's Kyowa Hakko to Develop RNAi Cancer Treatments; Dicerna Will Get $4 Million Upfront, $120 Million in Milestone Payments 1/4/2010 7:35:44 AM
Kyowa Hakko: Brain Imaging Study Confirms Cognizin(R) Citicoline Boosts Mental Function 6/8/2009 10:52:19 AM
Sanofi (France) (SAN.PA) Signs $315 Million Deal with Kyowa Hakko 5/20/2009 6:26:56 PM
Arana Therapeutics and Kyowa Hakko to Co-develop Anti-cancer Drug; Agreement Worth Up to $8M 4/24/2008 8:03:49 AM
Amgen (AMGN) Buys Licensing Rights from Kyowa Hakko; Amgen to Pay $100M Upfront 3/6/2008 7:07:08 AM
Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002) 2/28/2008 7:50:13 AM